Morgan Stanley 13D and 13G filings for Arcutis Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-06 4:00 pm Sale |
2024-09-30 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
MORGAN STANLEY MS |
3,993,787 3.400% |
-2,099,710 (-34.46%) |
Filing |
| 2024-02-12 09:52 am Purchase |
2023-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
MORGAN STANLEY MS |
6,093,497 6.500% |
6,093,497 (New Position) |
Filing |